JPRN-UMIN000008416
Completed
未知
Randomized phase II study of neoadjuvant chemotherapy with or without letrozole for postmenopausal ER-positive/HER2-negative breast cancers - KBCOG 10
Kobe Breast Cancer Oncology Group0 sites70 target enrollmentJuly 16, 2012
ConditionsPostmenopausal breast cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Postmenopausal breast cancer
- Sponsor
- Kobe Breast Cancer Oncology Group
- Enrollment
- 70
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Inflammatory breast cancer 2\) Bilateral breast cancers without DCIS or ICIS 3\) With multiple cancers diagnosed with 5 years 4\) With uncontrollable hypertension, angina pectoris, congestive heart failure 5\) With severe complication including infection or uncontrolled diabetes mellitus 6\) With viral hepatitis (HBs antigen\- or HCV antibody\-positive) 7\) Patients treated with endocrine therapy 8\) Infection or possible infection associated with clinical symptoms such as fever 9\) With severe edema 10\) With severe mental disorder 11\) Cases who physician judged improper to entry this trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma.retroperitoneal sarcomasMedDRA version: 20.0Level: LLTClassification code 10039494Term: Sarcoma NOSSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10077289Term: Retroperitoneal sarcomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-001085-37-FRInstitut Bergonié66
Completed
Phase 2
Randomized Phase II Study of Neoadjuvant Chemotherapy and Trastuzumab (Herceptin) for Operable Breast Cancer with Overexpression of HER2Breast CancerJPRN-UMIN000000651Office for cordination of Herceptin trial100
Recruiting
Phase 2
Randomized phase II trial of neoadjuvant Chemotherapy with Gemcitabine and S-1 vs. without neoadjuvant chemotherapy in patients with resectable pancreatic cancerResectable pancreatic cancerJPRN-UMIN000009822Chiba study group of adjuvant chemotherapy for pancreatic cancer74
Recruiting
Not Applicable
Randomized phase II study of neoadjuvant chemoradiotherapy (S-1+radiation) for resectable pancreatic cancer with less than 180 degree portal vein abutmentresectable pancreatic cancer with less than 180 degree portal vein abutmentJPRN-UMIN000027633agoya University, Graduate School of Medicine56
Active, not recruiting
Phase 1
Study of chemotherapy and immunotherapy for patients with lung cancer bounded in the thorax and potentially resectableon-small cell lung cancerMedDRA version: 20.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004515-45-ESFundación GECP90